A61P 19 - Drugs for skeletal disorders

Patents for A61P 19 - Drugs for skeletal disorders (81,981)
10/2002
10/09/2002	EP0973550B1 Antagonistic anti-avb3 integrin antibodies
10/09/2002	EP0964856B1 Bicyclic amino acids
10/09/2002	EP0904061B1 Pharmaceutical composition with base of rhein or diacerhein with improved biological availability
10/09/2002	CN1373763A Pteridinones and kinase inhibitors
10/09/2002	CN1373751A 'Alpha'-amino-'beta'-sulfonyl hydroxamic acid compounds
10/09/2002	CN1373662A 3(5)-amino-pyrazole derivs., process for their preparation and their use as antitumor agents
10/09/2002	CN1373660A Method for treating chronic pain using MEK inhibitors
10/09/2002	CN1372969A Medical liquor for treating rheuamtic arthritis ischias, etc
10/09/2002	CN1372961A Plaster and its preparing process
10/09/2002	CN1372959A Process for preparing patch 'Jingubitong'
10/09/2002	CN1372955A Oral liquid 'Gubao' and its preparing process
10/09/2002	CN1372950A Medicine for treating cervical vertebra disease and its preparing process
10/09/2002	CN1372948A Exterior-applied liquid medicine for promoting blood circulation, dispelling exogenous factor of wind and relaxing pain
10/09/2002	CN1372943A Medicine for treating rheumatoid and rheumatic arthritis by particular acupoint therapy
10/09/2002	CN1092066C Analgesic plaster for osteoarthritis
10/08/2002	WO2001080874A1 Bone-strengthening agents, food compositions for strengthening bone and feed compositions for strengthening bone
10/08/2002	US6462211 4-halogenated steroids, their preparation process and intermediates, their use as medicaments and the pharmaceutical compositions containing them
10/08/2002	US6462078 Antiinflammatory agents; library of plant extracts
10/08/2002	US6462076 Beta-amino acid nitrile derivatives as cathepsin K inhibitors
10/08/2002	US6462065 Use of 5-HT3 receptor antagonists for treating musculoeskeletal diseases
10/08/2002	US6462060 Heterocyclic-hydroxyimino-fluorene nuclei compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
10/08/2002	US6462038 Such as 1,2,3,6-tetrahydro-1-methyl-9-(trifluoromethyl)-7h-(1,4)oxazino(3,2 -g)quinolin-7-one; nonsteroidal, high affinity and specificity antagonists and agonists or partial agonists, i.e. partial and/or tissue specific activators
10/08/2002	US6462036 Inhibiting signal transduction by modulating activity of receptor and nonreceptor tyrosine and serine/threonine kinases to regulate and modulate abnormal or inappropriate cell proliferation, differentiation, or metabolism
10/08/2002	US6462020 N-formyl-met-leu-leu-phe-phe; inhibiting release of cytokines, histamines and leukotrienes; reducing adhesion, migration and aggregation of lymphocytes, eosinophils and neutrophils; rheumatoid arthritis
10/08/2002	US6462019 Inhibitors of proteasomal activity and production for stimulating bone growth
10/08/2002	US6461855 Microtubule stimulated atpase activity; cancer and nervous system disorder diagnosis
10/08/2002	US6461822 Therapeutic targets for agents that suppress the release of inflammatory mediators such as interleukin il-1 and il-1 beta
10/08/2002	CA2231046C Human protein kinases hyak3
10/03/2002	WO2002077217A2 Human dual specificity protein phosphatase 7-like protein
10/03/2002	WO2002077174A2 Human cytokine receptor
10/03/2002	WO2002077028A1 Polypeptides and nucleic acids for bolekine
10/03/2002	WO2002077017A2 Medical uses of intercellular communication facilitating compounds
10/03/2002	WO2002076995A2 2-amino-propanol derivatives
10/03/2002	WO2002076989A1 Protein phosphate inhibitors
10/03/2002	WO2002076986A1 Pyrazolopyrimidines as therapeutic agents
10/03/2002	WO2002076977A2 Rho-kinase inhibitors
10/03/2002	WO2002076976A2 Rho-kinase inhibitors
10/03/2002	WO2002076964A1 Derivatives of n-(arylsulfonyl)beta-aminoacids comprising a substituted aminomethyl group, the preparation method thereof and the pharmaceutical compositions containing same
10/03/2002	WO2002076957A1 Activator for peroxisome proliferator-activated receptor
10/03/2002	WO2002076953A1 New spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors
10/03/2002	WO2002076951A1 2-mercapto-4,5-diarylimidazole derivatives and the use thereof as cyclooxygenase inhibitors
10/03/2002	WO2002076948A1 Novel piperidine derivatives as modulators of chemokine receptors
10/03/2002	WO2002076946A2 Fused pyridine derivatives for use as vanilloid receptor antagonists for treating pain.
10/03/2002	WO2002076939A2 Cysteine protease inhibitors
10/03/2002	WO2002076930A2 Substituted diarylureas as stimulators for fas-mediated apoptosis
10/03/2002	WO2002076926A1 3,4-di-substituted cyclobutene-1, 2-diones as cxc chemokine receptor antagonists
10/03/2002	WO2002076508A1 Methods for delivering nucleic acid molecules into cells and assessment thereof
10/03/2002	WO2002076507A2 Uses of opg ligand to modulate immune responses
10/03/2002	WO2002076476A2 Prodrugs of anticancer agents employing substituted aromatic acids
10/03/2002	WO2002076457A1 Novel amides, preparation and therapeutic use as modulators of ccr-receptor activity
10/03/2002	WO2002076450A1 Dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
10/03/2002	WO2002076447A1 Hallogenated aminobenzophenones and aminobenzoylpyridines as inhibitors of il-1 and tnf
10/03/2002	WO2002076443A1 Use of breakers of advanced glycation endproducts for treating deleterious effects of aging and debilitating diseases
10/03/2002	WO2002076438A2 Flt-1 ligands and their uses in the treatment of diseases regulatable by angiogenesis
10/03/2002	WO2002076400A2 Inosine compounds and their use for treating or preventing an inflamation or a reperfusion disease
10/03/2002	WO2002076196A1 Transgenic animals expressing antibodies specific for genes of interest and uses thereof
10/03/2002	WO2002062794A3 Compounds
10/03/2002	WO2002062784A8 Piperidinee derivatives as neurokinin 1 antagonists
10/03/2002	WO2002062293A3 Coumarin compounds as microtubule stabilizing agents and therapeutic uses thereof
10/03/2002	WO2002046226A3 Trefoil factor 2 (tff2) peptides with moiety attached to asn15
10/03/2002	WO2002014349A3 Non-covalent inhibitors of urokinase and blood vessel formation
10/03/2002	WO2001071004A3 Proteases
10/03/2002	WO2001021812A9 Phosphatases which activate map kinase pathways
10/03/2002	WO2001019800A9 Mediators of hedgehog signaling pathways, compositions and uses related thereto
10/03/2002	WO2001019359A3 Medicaments containing pantothenic acid for the treatment of inflammatory joint disease
10/03/2002	US20020143149 Seven trans-membrane receptor-Fitz2
10/03/2002	US20020143145 Detcting moduators of binding activity of preferential membrane proteins; obtain animal, incubate with modulator, monitor adjustment in activity from recptors
10/03/2002	US20020143143 Peptides designed for the diagnosis and treatment of rheumatoid arthritis
10/03/2002	US20020143043 For therapy and prophylaxis of rheumatoid arthritis, or of allergic disorders, asthma, inflammation; inhibitors of the adhesion and migration of leucocytes and/or antagonists of adhesion receptor VLA-4 belonging to the integrins group
10/03/2002	US20020143032 Substituted 8-arylquinoline phosphodiesterase-4 inhibitors
10/03/2002	US20020143029 Tetrahydronaphthyridinyl-carboxamides having anti-convulsant activity
10/03/2002	US20020143026 Induce mitotic arrest thereby making them useful as anti-cancer agents; also for therapy of diseases which can be treated by inducing mitotic arrest
10/03/2002	US20020142996 Use of bisphosphonic acids for treating angiogenesis
10/03/2002	US20020142983 MUC-1 antagonists and methods of treating immune disorders
10/03/2002	US20020142963 Methods for increasing bone formation and enhancing bone accretion
10/03/2002	US20020142448 Antibody for use in the diagnosis, treatment and prevention of bone disorders and cancer
10/03/2002	US20020142353 Connective tissue growth factor (CTGF) and methods of use
10/03/2002	US20020142045 Cyclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect
10/03/2002	US20020141991 Methods of treating inflammatory disease using antibodies which bind GPR-9-6
10/03/2002	US20020141987 Fish serine proteinases and their pharmaceutical and cosmetic use
10/03/2002	US20020141977 Immunotherapy based on dendritic cells
10/03/2002	CA2442178A1 2-amino-propanol derivatives
10/03/2002	CA2441933A1 Novel amides, preparation and therapeutic use as modulators of ccr-receptor activity
10/03/2002	CA2441806A1 Inosine compounds and their use for treating or preventing an inflammation or a reperfusion disease
10/03/2002	CA2441700A1 Polypeptides and nucleic acids for bolekine
10/03/2002	CA2441599A1 Fused pyridine derivatives for use as vanilloid receptor antagonists for treating pain
10/03/2002	CA2441377A1 Protein phosphate inhibitors
10/03/2002	CA2441092A1 Dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
10/03/2002	CA2440676A1 Transgenic animals expressing antibodies specific for genes of interest and uses thereof
10/03/2002	CA2439961A1 Human cytokine receptor
10/03/2002	CA2439678A1 Uses of opg ligand to modulate immune responses
10/03/2002	CA2436351A1 3,4-di-substituted cyclobutene-1, 2-diones as cxc chemokine receptor antagonists
10/03/2002	CA2434020A1 Substituted diarylureas as stimulators for fas-mediated apoptosis
10/02/2002	EP1245676A1 Human monoclonal antibodies against tgf-beta ii receptor and medicinal use thereof
10/02/2002	EP1245562A1 5-THIA-$g(v)-(SUBSTITUTED PHENYL)-PROSTAGLANDIN E ALCOHOLS, PROCESS FOR PREPARING THE ALCOHOLS AND PHARMACEUTICAL PREPARATIONS CONTAINING THE SAME AS THE ACTIVE INGREDIENT
10/02/2002	EP1245229A2 Methods and compositions for inhibition of angiogenesis
10/02/2002	EP1244807A1 Il-6 like polynucleotide
10/02/2002	EP1244790A2 Nucleic acids encoding polypeptides having chips activity
10/02/2002	EP1244781A2 Antisense oligonucleotides
10/02/2002	EP1244702A2 A process for isolation of osteopontin from milk

1 ... 630 631 632 633 634 635 636 637 638 639 640 641 642 643 644 645 646 647 648 649 650 ... 820